-
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for CLL/SLL Patients in China
PharmaSources
March 28, 2025
InnoCare announced the first patient dosed in the Phase III trial of ICP-248 combined with orelabrutinib for CLL/SLL. It's a potential treatment, with other trials advancing.
-
InnoCare Releases 2024 Results and Business Highlights
PharmaSources
March 27, 2025
InnoCare announced 2024 annual results, including financials, R&D progress in oncology and autoimmune diseases, and globalization efforts.
-
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China
PharmaSources
March 20, 2025
InnoCare announced the first patient dosing in the Phase III trial of ICP - 488 for psoriasis. It showed good results in Phase II, aiming to meet unmet needs.
-
Global Shingles (Herpes Zoster) Market Trends and Prospects
David Orchard-Webb
March 18, 2025
The global shingles market is growing due to factors like an aging population. It elaborates on drivers, segmentation, competition, and future trends.
-
The Global Alpha-Glucosidase Inhibitor Market: Trends and Prospects
David Orchard-Webb
March 18, 2025
Alpha-glucosidase inhibitors are used for type 2 diabetes. This article analyzes their market, including growth, segments, and challenges.
-
Is the Practice of "Prioritizing Biologics over Small Molecule Drugs" Justified?
Krebs Qin
March 14, 2025
The article compares small molecule drugs and biologics in development, cost, etc., questions biologic - preferential policies, and mentions related acts for policy correction.
-
Top 10 Sales Volume of New Drugs of Traditional Chinese Medicine: Behind the Numbers - Only 2 Out of 29 Surpassed RMB 100 Million in Sales
Xiao Yan
March 14, 2025
From 2016 - 2024, TCM new drugs made progress but lagged in sales. This article analyzes reasons and explores future directions.
-
A Decade of Transformation in China's Innovative Drug Industry: The Journey from Follower to Leader
Kevin
March 14, 2025
Over the past decade, China's innovative drug market has experienced remarkable transformation and growth. With the combined drive of policies, technology, and capital, China's innovative drug industry has entered a golden period of growth. This paper pro
-
Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD
PharmaSources
March 11, 2025
InnoCare Pharma; TYK2 inhibitor ICP - 488; psoriasis; 2025 AAD Annual Meeting; clinical data
-
What are Data-Driven Strategies for Quality Control Optimization
Muhammad Asim Niazi
March 05, 2025
Quality Control systematically checks drugs, raw materials, and finished products at various production stages for efficacy and safety.